DNA Priming for Seasonal Influenza Vaccine: A Phase 1b Double-Blind Randomized Clinical Trial

• Published in: PloS one Vol. 10; no. 5; p. e0125914
• Main Authors: Ledgerwood, Julie E., Bellamy, Abbie R., Belshe, Robert, Bernstein, David I., Edupuganti, Srilatha, Patel, Shital M., Renehan, Phyllis, Zajdowicz, Thad, Schwartz, Richard, Koup, Richard, Bailer, Robert T., Yamshchikov, Galina V., Enama, Mary E., Sarwar, Uzma, Larkin, Brenda, Graham, Barney S.
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 07.05.2015; Public Library of Science (PLoS)
• Subjects: Adult; Adults; Aged; Antibody response; Antigens; At risk populations; Avian flu; Care and treatment; Clinical trials; Deoxyribonucleic acid; DNA; DNA vaccines; Double-Blind Method; Double-blind studies; FDA approval; Female; Hemagglutination; Hemagglutination inhibition; Hospitals; Humans; Immune response; Immunity; Immunogenicity; Infectious diseases; Influenza; Influenza A Virus, H5N1 Subtype - genetics; Influenza A Virus, H5N1 Subtype - immunology; Influenza vaccines; Influenza Vaccines - administration & dosage; Influenza Vaccines - adverse effects; Influenza Vaccines - immunology; Influenza, Human - prevention & control; Injections, Intramuscular; Licenses; Male; Manufacturing; Medicine; Middle Aged; Optimization; Pandemics; Patient outcomes; Phosphates; Prevention; Priming; Production capacity; Risk factors; Seasons; Studies; Swine flu; Vaccines; Vaccines, DNA - administration & dosage; Vaccines, DNA - adverse effects; Vaccines, DNA - immunology; Vaccines, Inactivated - administration & dosage; Vaccines, Inactivated - immunology; Young Adult; California

The efficacy of current influenza vaccines is limited in vulnerable populations. DNA vaccines can be produced rapidly, and may offer a potential strategy to improve vaccine immunogenicity, indicated by studies with H5 influenza DNA vaccine prime followed by inactivated vaccine boost. Four sites enro...